Consiglio Nazionale Delle Ricerche

Sifi S.p.a.

University of Kentucky Research Foundation

Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw

Life Sciences Research Partners Vzw

Tecnogen S.c.p.a.

Ministero Dell Universita'e Della Ricerca Scientifica E Tecnologica (m.u.r.s.t. )

Anbition S.r.l.

D. Collen Research Foundation Vzw

Sandro De Falco

Giorgio Fassina

Santa Viola

Ilenia Abbate

Cristina Maria Concetta Zappulla

Manuela Santonocito

Elena Solfato

Francesco Giuliano

Jayakrishna Ambati

Peter Carmeliet

Désiré Collen

Antonio Verdoliva

Menotti Ruvo

Davide Rosiello

Ruvo Menotti

Desire Collen

The present invention relates to peptides, a composition comprising said peptides and the use thereof as inhibitors of angiogenesis and/or neoangiogenesis. Furthermore, the present invention relates to the use of said peptides and said composition for the treatment of pathologies correlated with an incorrect angiogenesis and/or neoangiogenesis. In particular, in this context reference is made to angiogenesis and/or neoangiogenesis correlated with VEGFR1.

Peptides and medical uses thereof

Provided are oil-in-water microemulsions for formulating pharmaceutically active compounds. The microemulsions contain oils, surfactants, water, and the pharmaceutical compounds, and are produced by mixing an aqueous phase and a lipid phase in which each phase contains at least one surfactant in a defined ratio whereby the resulting microemulsion has very small dispersed particles and is thermodynamically very stable.

Microemulsion compositions

Provided are oil-in-water microemulsions for formulating pharmaceutically active compounds. The microemulsions contain oils, surfactants, water, and the pharmaceutical compounds, and are produced by mixing an aqueous phase and a lipid phase in which each phase contains at least one surfactant in a defined ratio whereby the resulting microemulsion has very small dispersed particles, and, is thermodynamically very stable.

A method of suppressing angiogenesis involves administering to a subject an isolated Fc fragment of an IgG1 antibody, or an IgG1 antibody.

Methods of administering IgG1 antibodies and methods of suppressing angiogenesis

The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monoclonal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.

Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage

Pharmaceutical composition containing an inhibitor of immunoglobulin-receptor interaction

Disclosed herein are uses of a recombinant protein as a receptor for a hepatitis virus. Also disclosed are a nucleic acid coding for the receptor, a vector comprising a nucleic acid encoding the receptor, a host cell transformed or transfected with the nucleic acid, and a new recombinant protein having the biological property to act as a receptor for a hepatitis virus and a transgenic animal expressing the recombinant protein.

Use of a recombinant protein as receptor of a hepatitis virus

Growing community of inventors

Naples, Italy

Sandro De Falco